John Webster, MD
Urology · Boulder, CONPI 1881608768
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,015 of the $25,332 with a category attached, or 75.1%. Medtronic accounts for 88.2% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $13,263, more than ten times the $640 reported in 2019. Among urology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $207.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$22K
- Neotract Inc.$587
- AbbVie$290
- Boston Scientific$262
- Axonics, Inc.$248
- Teleflex LLC$224
- plus $1K from 17 others
Across 2 payments — averaging $565.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1K
What the payments were for
- Consulting fees$19,01575%
- Speaking & faculty fees$3,25013%
- Travel & lodging$2841%
- Food & beverage$2,78311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $22,339 |
| Neotract Inc. | 10 | $587 |
| AbbVie(2 entities) | 16 | $290 |
| Boston Scientific | 14 | $262 |
| Axonics, Inc. | 11 | $248 |
| Teleflex LLC | 5 | $224 |
| Johnson & Johnson | 5 | $221 |
| Procept Biorobotics Corporation | 3 | $183 |
| Myovant Sciences Inc. | 6 | $109 |
| AstraZeneca | 1 | $107 |
| Sumitomo Pharma America, Inc. | 5 | $104 |
| Rochester Medical Corporation | 5 | $90 |
| Astellas Pharma US Inc | 4 | $85 |
| Pfizer | 4 | $80 |
| Merck | 3 | $73 |
| Olympus America Inc. | 3 | $64 |
| Dendreon Pharmaceuticals LLC | 2 | $63 |
| Coloplast | 2 | $46 |
| Progenics Pharmaceuticals, Inc. | 2 | $44 |
| Convatec Inc. | 1 | $41 |
| Bayer | 1 | $31 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $27 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALLEYLAB FT10$9,250
- UroLift$513
- AquaBeam Robotic System$149
- Erleada$121
How this compares
$25,332 in reported general payments places this provider in the 90th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 124 | $116,947 |
| OrgovyxRelugolix | 20 | $51,328 |
| Methenamine Hippurate | 90 | $10,536 |
| GemtesaVibegron | 11 | $8,843 |
| Tamsulosin Hcl | 268 | $3,758 |
| Abiraterone Acetate | 13 | $2,590 |
| Trimethoprim | 23 | $1,888 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 50 | $1,130 |
| Testosterone Cypionate | 24 | $883 |
| Finasteride | 78 | $753 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $707 |
| Estradiol | 13 | $593 |
| Oxybutynin Chloride ErOxybutynin Chloride | 32 | $485 |
| Nortriptyline Hcl | 14 | $304 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $85 | $116,947124 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $104 | $60,17131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 urology providers in Colorado.
Other urology in Boulder
- John KeferBoulder$68K
- James ClarkBoulder$9K
- Stephen SiegelBoulder$7K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.